Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2024
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Alzheimer's disease (early) - gantenerumab [ID6142]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC